NN has filed a prospectus for an offering of 24.51M common shares on behalf of selling shareholders. The filing was submitted to the SEC, detailing the terms of the offering. The shares are being offered by existing shareholders, and the company will not receive any proceeds from the sale.

The prospectus outlines the specifics of the offering, including the number of shares and the parties involved. The selling shareholders are responsible for the shares being offered, and NN's role is limited to facilitating the filing.

Offering Details

The prospectus provides all necessary information for potential investors. The offering is subject to market conditions and regulatory approvals. NN has confirmed that the shares are being sold solely by the selling shareholders.

NN, Inc. has secured initial purchase orders to manufacture precision components for a leading robotic-assisted surgery platform, marking a breakthrough in its Medical Products business. The company successfully passed a critical full-facility audit at its Kentwood, Michigan plant, enabling it to qualify for this new market segment. This development follows a multi-year investment program and the installation of a new quality system to meet medical industry standards.

The new customer has released purchase orders with immediate delivery and ramp-up requirements. This milestone complements NN's legacy medical work in surgical instruments, orthopedic tools, and electrosurgical products. With this advancement, NN's medical new business pipeline has increased by approximately $25 million, bringing the total to about $75 million. This figure represents a meaningful component of the company's total corporate new business pipeline, which exceeds $750 million across all products and markets.

Medical Products Growth Program

NN's strategy to penetrate the medical market includes several key components:

• Specialized quality control systems
• Dedicated CNC machining equipment
• Special purpose floor space
• Medical industry experts on staff
• State-of-the-art stainless steel machined products
• Global footprint in North America, China, South America, and Europe

Strategic Positioning

Robotic-assisted surgery is expanding at double-digit annual rates in the United States, presenting a secular growth opportunity for precision component suppliers. NN is leveraging its engineering capability, quality systems, and global manufacturing footprint to capture this demand. The company is actively investing in the medical market through dedicated staff, tradeshow attendance, and additional equipment.

Harold Bevis, President and Chief Executive Officer of NN, Inc., stated that the achievement is a direct payoff on investments made over the last three years. He noted that upgrading the quality system to the medical level was a necessary step that has now been completed. Bevis emphasized that the company is successfully executing on its growth goals in the medical products market and intends to grow with this new customer while participating in the broader medical market.

NN plans to combine this new win information with recent successes in the Data Center sector to adjust its 2026 sales, adjusted EBITDA, and New Wins guidance during its next business update in August.